Thought Leadership

Latest Report

Thumbnail

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

Biopharma was not exempt from the initial shock of a global pandemic, but the worst projections have not happened and the initial beneficiaries have now emerged. After a near universal first quarter stumble, big and medium cap pharma companies finished the half in style, with stocks up $190bn since the end of 2019. The picture is even better for…

Report library

Thumbnail

Evaluate Vantage COVID-19 Report

Biopharma and Medtech are leading the fight against COVID-19, but are not immune from the significant economic impact of the pandemic. The COVID-19 pandemic is having a…

Thumbnail

EvaluatePharma Orphan Drug Report 2020

What will the orphan drug landscape look like in 2024? Big pharma's recent dominance of the orphan market has fuelled calls to reform the orphan drug act in the US.…

Thumbnail

Evaluate Vantage 2020 Preview

The Evaluate Vantage 2020 Preview predicts a rocky year ahead, with areas of significant growth contrasting with investor uncertainty. The industry closed 2019 with a…